Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations – a registry based analysis
Jan Moritz Middeke, Raphael Teipel, Christoph Röllig, Sebastian Stasik, Armin Zebisch, Heinz Sill, Michael Krämer, Sebastian Scholl, Andreas Hochhaus, Edgar Jost, Tim H. Brümmendorf, Ralph Naumann, Björn Steffen, Hubert Serve, Heidi Altmann, Volker Kunzmann, Hermann Einsele, Stefani Parmentier, Markus Schaich, Andreas Burchert, Andreas Neubauer, Christoph Schliemann, Wolfgang E. Berdel, Katja Sockel, Friedrich Stölzel, Uwe Platzbecker, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, for the Study Alliance Leukemia (SAL)
Abstract
We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (whole cohort) was 30% with a median overall survival of 4.7 months. First-line patients achieved better responses than r/r-patients (ORR: 38% vs. 21%) resulting in a median OS of 5.8 months vs. 3.9 months. NGS based mutation analysis was performed in 180 patients. 20 patients (11%) harbored a TP53 mutation. Response rates and survival did not differ significantly between TP53 mutated patients and wild-type patients. This analysis of a large cohort of AML patients provides response rates and OS data after decitabine treatment. Interestingly, outcome was not negatively influenced by a TP53 mutation.